To study the safety and efficacy of adult stem cell therapy in treating end stage lung diseases

Phase-I/II open label,safety and efficacy study of autologous adult stem cell therapy in end stage lung diseases-A pilot study

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/02/005569

Enrollment

Registered

2015-02-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- COPD and IPF

Interventions

Intervention1: Open label Single arm: 13 million cells single dose central line Control Intervention1: Single arm: COPD,IPF Control Intervention2: Not applicable: Not applicable

Eligibility

Inclusion criteria

Inclusion criteria: Ineffective clinical treatment,Limited physical activity,cessation of smoking for >6 months

Exclusion criteria

Exclusion criteria: Patient on ventilator,Diagnosis of malignancy,H/o severe CAD,Significant liver kidney disease,psychiatric illness,Active smoker,Consent not given,Pregnancy,Diagnosed case of HIV,active TB,Secondary infections

Design outcomes

Primary

Measure	Time frame
Safety without any adverse event [AE] in the studyTimepoint: 24 months	—

Secondary

Measure	Time frame
Pulmonary function tests,Exercise capability and Quality of lifeTimepoint: 2 years	—

Countries

India

Contacts

Public ContactDr Mohammed Samiuddin

Global Hospitals

lkiran@globalhospitalsindia.com040-30244501

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026